Author Title [ Type(Desc)] Year
Filters: Author is Sawa, Yoshiki  [Clear All Filters]
Journal Article
Kido T, Miyagawa S, Goto T, Tamai K, Ueno T, Toda K, Kuratani T, Sawa Y. The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster. PLoS One. 2018;13(12):e0202838.
Miyagawa S, Sawa Y. Building a new strategy for treating heart failure using Induced Pluripotent Stem Cells. J Cardiol. 2018.
Mori D, Miyagawa S, Yajima S, Saito S, Fukushima S, Ueno T, Toda K, Kawai K, Kurata H, Nishida H, et al. Cell Spray Transplantation of Adipose-Derived Mesenchymal Stem Cell Recovers Ischemic Cardiomyopathy in a Porcine Model. Transplantation. 2018.
Yoshida S, Miyagawa S, Matsuzaki T, Ishii Y, Fukuda-Kawaguchi E, Kawamura T, Kawamura A, Nakamura Y, Toda K, Sawa Y. Chimerism through the activation of invariant natural killer T cells prolongs graft survival after transplantation of induced pluripotent stem cell-derived allogeneic cardiomyocytes. PLoS One. 2022;17(3):e0264317.
Ohashi F, Miyagawa S, Yasuda S, Miura T, Kuroda T, Itoh M, Kawaji H, Ito E, Yoshida S, Saito A, et al. CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells. Sci Rep. 2019;9(1):4638.
Amano Y, Nishiguchi A, Matsusaki M, Iseoka H, Miyagawa S, Sawa Y, Seo M, Yamaguchi T, Akashi M. Development of Vascularized iPSC Derived 3D-Cardiomyocyte Tissues by Filtration Layer-by-Layer Technique and Their Application for Pharmaceutical Assays. Acta Biomater. 2016.
Takeda M, Ito E, Minami K, Harada A, Mochizuki-Oda N, Sawa Y, Miyagawa S. Elimination of residual undifferentiated induced pluripotent stem cells (iPSCs) using irradiation for safe clinical applications of iPSC-derived cardiomyocytes. Biochem Biophys Res Commun. 2021;574:91-96.
Nakazato T, Kawamura T, Uemura T, Liu L, Li J, Sasai M, Harada A, Ito E, Iseoka H, Toda K, et al. Engineered three-dimensional cardiac tissues maturing in a rotating wall vessel bioreactor remodel diseased hearts in rats with myocardial infarction. Stem Cell Reports. 2022.
Higuchi T, Miyagawa S, Pearson JT, Fukushima S, Saito A, Tsuchimochi H, Sonobe T, Fujii Y, Yagi N, Astolfo A, et al. Functional and Electrical Integration of Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Myocardial Infarction Rat Heart. Cell Transplant. 2015.
Kuramoto Y, Naito AT, Tojo H, Sakai T, Ito M, Shibamoto M, Nakagawa A, Higo T, Okada K, Yamaguchi T, et al. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient. J Mol Cell Cardiol. 2018.
Goto T, Miyagawa S, Tamai K, Matsuura R, Kido T, Kuratani T, Shimamura K, Sakaniwa R, Harada A, Sawa Y. High-mobility group box 1 fragment suppresses adverse post-infarction remodeling by recruiting PDGFRα-positive bone marrow cells. PLoS One. 2020;15(4):e0230392.
Yokoyama J, Miyagawa S, Akagi T, Akashi M, Sawa Y. Human induced pluripotent stem cell-derived three-dimensional cardiomyocyte tissues ameliorate the rat ischemic myocardium by remodeling the extracellular matrix and cardiac protein phenotype. PLoS One. 2021;16(3):e0245571.
Sougawa N, Miyagawa S, Fukushima S, Yokoyama J, Kitahara M, Harada A, Mochizuki-Oda N, Sato-Nishiuchi R, Sekiguchi K, Sawa Y. Laminin-511 Supplementation Enhances Stem Cell Localization with Suppression in the Decline of Cardiac Function in Acute Infarct Rats. Transplantation. 2019.
Kainuma S, Miyagawa S, Toda K, Yoshikawa Y, Hata H, Yoshioka D, Kawamura T, Kawamura A, Kashiyama N, Ito Y, et al. Long-term Outcomes of Autologous Skeletal Myoblast Cell-sheet Transplantation for End-stage Ischemic Cardiomyopathy. Mol Ther. 2021.
Kashiyama N, Miyagawa S, Fukushima S, Kawamura T, Kawamura A, Yoshida S, Eiraku S, Harada A, Matsunaga K, Watabe T, et al. MHC-mismatched Allotransplantation of Induced Pluripotent Stem Cell-Derived Cardiomyocyte Sheets to Improve Cardiac Function in A Primate Ischemic Cardiomyopathy Model. Transplantation. 2019.
Kawamura T, Miyagawa S, Fukushima S, Yoshida A, Kashiyama N, Kawamura A, Ito E, Saito A, Maeda A, Eguchi H, et al. N-Glycans: Phenotypic Homology and Structural Differences between Myocardial Cells and Induced Pluripotent Stem Cell-Derived Cardiomyocytes. PLoS One. 2014;9(10):e111064.
Qu X, Li J, Liu L, Zhang J, Hua Y, Suzuki K, Harada A, Ishida M, Yoshida N, Okuzaki D, et al. ONO-1301 enhances post-transplantation survival of human induced pluripotent stem cell-derived cardiac tissue sheet by promoting angiogenesis. J Heart Lung Transplant. 2023.
Sawa Y, Miyagawa S. Present and Future Perspectives on Cell Sheet-Based Myocardial Regeneration Therapy. Biomed Res Int. 2013;2013:583912.
Masuda S, Miyagawa S, Fukushima S, Kawamura T, Kashiyama N, Saito A, Sawa Y. Regulating ES or Induced Pluripotent Stem Cells by Innate Lymphoid Cells. Transplantation. 2014;98(5):e38-e39.
Ishida M, Miyagawa S, Saito A, Fukushima S, Harada A, Ito E, Ohashi F, Watabe T, Hatazawa J, Matsuura K, et al. Transplantation of human induced pluripotent stem cell-derived cardiomyocytes is superior to somatic stem cell therapy for restoring cardiac function and oxygen consumption in a porcine model of myocardial infarction. Transplantation. 2018.
Kashiyama N, Miyagawa S, Fukushima S, Kawamura T, Kawamura A, Yoshida S, Nakamura Y, Harada A, Masuda H, Toda K, et al. Vasculogenically conditioned peripheral blood mononuclear cells inhibit mouse immune response to induced pluripotent stem cell-derived allogeneic cardiac grafts. PLoS One. 2019;14(5):e0217076.
Kawamura M, Miyagawa S, Fukushima S, Saito A, Toda K, Daimon T, Shimizu T, Okano T, Sawa Y. Xenotransplantation of Bone Marrow-Derived Human Mesenchymal Stem Cell Sheets Attenuates Left Ventricular Remodeling in a Porcine Ischemic Cardiomyopathy Model. Tissue Eng Part A. 2015.